McGuinness et al v. GlaxoSmithKline, LLC
| Douglas Kaplan and Mary McGuinness |
| GlaxoSmithKline, LLC |
| 1:2019cv11115 |
| May 14, 2019 |
| US District Court for the District of Massachusetts |
| F Dennis Saylor |
| Personal Inj. Prod. Liability |
| 28 U.S.C. ยง 1332 |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 9, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 8 NOTICE TO TELEPHONE PARTICIPANTS: Please use the following Participant line: (800) 459-5346 and Conference ID: Zofran for the Status Conference set for July 10, 2019 at 1:30 PM Associated Cases: 1:15-md-02657-FDS et al.(Bono, Christine) |
| Filing 7 Judge F. Dennis Saylor, IV: ORDER entered. MDL Order No. 34. ORDER FURTHER SUPPLEMENTING AND MODIFYING MDL ORDER NOS. 30 AND 31. Associated Cases: 1:15-md-02657-FDS et al.(Bono, Christine) |
| Filing 6 Electronic Clerk's Notes for proceedings held before Judge F. Dennis Saylor, IV: Status Conference held on 6/11/2019.(1) The Court heard updates on the current total of federal and state filings.(2) The Court heard updates on Phase 5 fact discovery. (3) The Court heard updates on Phase 5 expert discovery, including Magistrate Judge Dein's recently issued order on plaintiffs motions to compel in Fluth v. GSK, Case No. 1:17-cv-10066. (4) The Court heard updates on Phase 5, Group 1 trial selections, including Rodriguez v. GSK, Case No. 1:15-cv-13762, the first case selected for trial.(5) A colloquy was held about how the Court should proceed in light of the United States Supreme Court's recently issued decision in Merck Sharp & Dohme Corp. v. Albrecht. The parties will have until 7/1/2019 to file any additional briefing on the question of preemption, such as a renewed motion for summary judgment. Any oppositions will be due 7/9/2019. The Court will take the matter up at the 7/10/2019 status conference.(6) A colloquy was held about trial logistics and setting a timetable for further pretrial filings.(7) The Court heard updates on GSK's motion for summary judgment based on lack of general causation evidence, and a colloquy was held about filing logistics. (Court Reporter: Valerie OHara at vaohara@gmail.com.)(Attorneys present: Various) Associated Cases: 1:15-md-02657-FDS et al.(Pezzarossi, Lisa) |
| Filing 5 NOTICE of Appearance by Jennifer M. Stevenson on behalf of GlaxoSmithKline, LLC (Stevenson, Jennifer) |
| Filing 4 Summons Issued as to All Defendants. Counsel receiving this notice electronically should download this summons, complete one for each defendant and serve it in accordance with Fed.R.Civ.P. 4 and LR 4.1. Summons will be mailed to plaintiff(s) not receiving notice electronically for completion of service. (Coppola, Katelyn) |
| Filing 3 NOTICE OF MDL CASE OPENED, Direct file in the District of Massachusetts; McGuinness, et al v. GlaxoSmithKline, LLC. In Re: Zofran (Ondansetron) Products Liability Litigation, MDL 2657. (Finn, Mary) |
| Filing 2 ELECTRONIC NOTICE of Case Assignment. Judge F. Dennis Saylor, IV assigned to case. (Finn, Mary) |
| Filing 1 COMPLAINT against GlaxoSmithKline, LLC Filing fee: $ 400, receipt number 0101-7684134 (Fee Status: Filing Fee paid), filed by Douglas Kaplan, Mary McGuinness. (Attachments: #1 Civil Cover Sheet, #2 Category Form)(Ayala, Thomas) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Massachusetts District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
